| scholarly article | Q13442814 |
| P356 | DOI | 10.1038/CLPT.1991.155 |
| P698 | PubMed publication ID | 1914374 |
| P2093 | author name string | W E Evans | |
| C F Stewart | |||
| S G Arbuck | |||
| R A Fleming | |||
| P433 | issue | 4 | |
| P921 | main subject | etoposide | Q418817 |
| P304 | page(s) | 385-393 | |
| P577 | publication date | 1991-10-01 | |
| P1433 | published in | Clinical Pharmacology & Therapeutics | Q1101529 |
| P1476 | title | Relation of systemic exposure to unbound etoposide and hematologic toxicity | |
| P478 | volume | 50 |
| Q33913894 | Adaptive control methods for the dose individualisation of anticancer agents |
| Q46183978 | An interface model for dosage adjustment connects hematotoxicity to pharmacokinetics |
| Q72175723 | Assessment of toxicokinetics and toxicodynamics following intravenous administration of etoposide phosphate in beagle dogs |
| Q73097603 | Bioequivalence assessment of etoposide phosphate and etoposide using pharmacodynamic and traditional pharmacokinetic parameters |
| Q71855371 | Determination of unbound etoposide concentration in ultrafiltered plasma by high-performance liquid chromatography with fluorimetric detection |
| Q86706636 | Determination of unbound fraction of pazopanib in vitro and in cancer patients reveals albumin as the main binding site |
| Q72814523 | Disposition of total and unbound etoposide following high-dose therapy |
| Q35965798 | Effects of food on the clinical pharmacokinetics of anticancer agents: underlying mechanisms and implications for oral chemotherapy |
| Q37338767 | Elevated alpha1-acid glycoprotein in gastric cancer patients inhibits the anticancer effects of paclitaxel, effects restored by co-administration of erythromycin |
| Q71129548 | Etoposide combined with interferon alfa-2b: novel exploitation of established etoposide pharmacokinetics and pharmacodynamics |
| Q40694372 | Etoposide dosage and pharmacodynamics |
| Q40918065 | Etoposide for the treatment of paediatric tumours: what is the best way to give it? |
| Q34510289 | High-performance liquid chromatographic methods for the determination of topoisomerase II inhibitors |
| Q71795327 | High-performance liquid chromatography with fluorometric detection for monitoring of etoposide and its cis-isomer in plasma and leukaemic cells |
| Q36765396 | Integration of animal pharmacokinetic and pharmacodynamic data in drug safety assessment |
| Q40755248 | Limited-sampling models for anticancer agents |
| Q35041437 | Multiple-pool cell lifespan model of hematologic effects of anticancer agents |
| Q43936366 | Oral etoposide in patients with hematological malignancies: a clinical and pharmacokinetic study |
| Q40694367 | Pharmacodynamics and long-term toxicity of etoposide |
| Q52422246 | Pharmacodynamics of three daily infusions of etoposide in patients with extensive-stage small-cell lung cancer |
| Q41440111 | Pharmacokinetic optimisation of cancer chemotherapy. Effect on outcomes |
| Q35771512 | Pharmacokinetic optimisation of treatment with oral etoposide. |
| Q41558088 | Pharmacokinetic studies in cancer chemotherapy: usefulness in clinical practice |
| Q101166170 | Pharmacokinetic-pharmacodynamic modelling of the hypoglycaemic effect of pulsatile administration of human insulin in rats |
| Q35579412 | Pharmacology of Anticancer Drugs in the Elderly Population |
| Q28365888 | Population pharmacokinetics and pharmacodynamics of oral etoposide |
| Q91814732 | Population pharmacokinetics of carboplatin, etoposide and melphalan in children: a re-evaluation of paediatric dosing formulas for carboplatin in patients with normal or mild impairment of renal function |
| Q77761715 | Practical treatment guide for dose individualisation in cancer chemotherapy |
| Q36421762 | Randomized comparison of etoposide pharmacokinetics after oral etoposide phosphate and oral etoposide |
| Q40694954 | Simultaneous determination of etoposide and its catechol metabolite in the plasma of pediatric patients by liquid chromatography/tandem mass spectrometry |
| Q41139560 | The clinical pharmacology of etoposide: an update |
| Q40911128 | Therapeutic drug monitoring opportunities in cancer therapy |
| Q40694376 | Use of etoposide in patients with organ dysfunction: pharmacokinetic and pharmacodynamic considerations |
Search more.